Correlation Engine 2.0
Clear Search sequence regions

  • atazanavir (1)
  • CYP2C9 (5)
  • cytosol (1)
  • glucuronides (2)
  • gout (3)
  • human (4)
  • isoforms (2)
  • liver (2)
  • oxazines (2)
  • P 450 (2)
  • patients (1)
  • pyridines (2)
  • UGT1A1 (5)
  • UGT1A3 (1)
  • Sizes of these terms reflect their relevance to your search.

    UR-1102, a novel uricosuric agent for treating gout, has been confirmed to exhibit a pharmacological effect in patients. We clarified its metabolic pathway, estimated the contribution of each metabolic enzyme, and assessed the impact of genetic polymorphisms using human in vitro materials. Glucuronide, sulfate and oxidative metabolites of UR-1102 were detected in human hepatocytes. The intrinsic clearance by glucuronidation or oxidation in human liver microsomes was comparable, but sulfation in the cytosol was much lower, indicating that the rank order of contribution was glucuronidation ≥ oxidation > sulfation. Recombinant UGT1A1 and UGT1A3 showed high glucuronidation of UR-1102. We took advantage of a difference in the inhibitory sensitivity of atazanavir to the UGT isoforms and estimated the fraction metabolised (fm) with UGT1A1 to be 70%. Studies using recombinant CYPs and CYP isoform-specific inhibitors showed that oxidation was mediated exclusively by CYP2C9. The effect of UGT1A1 and CYP2C9 inhibitors on UR-1102 metabolism in hepatocytes did not differ markedly between the wild type and variants.


    Mizuki Yamane, Fumihiko Igarashi, Tsuyoshi Yamauchi, Toshito Nakagawa. Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout. Xenobiotica; the fate of foreign compounds in biological systems. 2021 Jan;51(1):61-71

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32813611

    View Full Text